| Medical and Health Sciences | Lifetime | 285 | US 155 | 99.99 |
| Biological Sciences | Lifetime | 839 | US 457 | 99.90 |
| Molecular Biology | Lifetime | 498 | US 311 | 99.76 |
| Reproductive Medicine | Lifetime | 61 | US 26 | 99.66 |
| Cancer Research | Lifetime | 92 | US 54 | 99.51 |
| Oncology | Lifetime | 217 | US 118 | 99.66 |
| Pulmonary and Respiratory Medicine | Lifetime | 349 | US 191 | 99.57 |
| Materials Chemistry | Lifetime | 849 | US 237 | 99.08 |
| Medical Physiology | Lifetime | 822 | US 421 | 98.47 |
| Psychiatry and Mental health | Lifetime | 522 | US 264 | 98.18 |
| Obstetrics and Gynecology | Lifetime | 349 | US 158 | 97.51 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 310 | US 97 | 97.09 |
| Reproductive Medicine | 2021-2025 | 121 | US 35 | 95.16 |
| Surgery | 2021-2025 | 628 | US 240 | 94.58 |
| Oncology | 2021-2025 | 491 | US 216 | 93.55 |
| Cancer Research | 2021-2025 | 423 | US 168 | 68.23 |
| Ovarian cancer diagnosis and treatment | Lifetime | 3 | US 2 | 99.92 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 1 | US 1 | 99.94 |
| MicroRNA in disease regulation | Lifetime | 29 | US 17 | 99.79 |
| Cancer-related molecular mechanisms research | Lifetime | 88 | US 34 | 99.49 |
| Angiogenesis and VEGF in Cancer | Lifetime | 33 | US 16 | 99.68 |
| Endometrial and Cervical Cancer Treatments | Lifetime | 66 | US 38 | 99.50 |
| RNA Interference and Gene Delivery | Lifetime | 204 | US 104 | 99.32 |
| Cancer Genomics and Diagnostics | Lifetime | 236 | US 151 | 99.50 |
| Chronic Obstructive Pulmonary Disease (COPD) Research | Lifetime | 178 | US 63 | 99.24 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 57 | US 17 | 97.97 |
| Cancer Mechanisms and Therapy | Lifetime | 97 | US 52 | 98.83 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 67 | US 33 | 98.99 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 477 | US 228 | 98.67 |
| Cancer Cells and Metastasis | Lifetime | 299 | US 141 | 98.62 |
| Carbon Nanotubes in Composites | Lifetime | 267 | US 88 | 98.70 |
| Circular RNAs in diseases | Lifetime | 278 | US 59 | 98.12 |
| Cancer, Lipids, and Metabolism | Lifetime | 368 | US 191 | 98.53 |
| Asthma and respiratory diseases | Lifetime | 590 | US 217 | 98.65 |
| PARP inhibition in cancer therapy | Lifetime | 183 | US 94 | 97.42 |
| Endometriosis Research and Treatment | Lifetime | 357 | US 113 | 97.94 |
| Plant tissue culture and regeneration | Lifetime | 583 | US 170 | 97.71 |
| Prostate Cancer Treatment and Research | Lifetime | 701 | US 377 | 98.07 |
| Cancer survivorship and care | Lifetime | 432 | US 215 | 97.31 |
| Cancer-related Molecular Pathways | Lifetime | 742 | US 388 | 97.59 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 603 | US 293 | 98.13 |
| Renal cell carcinoma treatment | Lifetime | 641 | US 340 | 97.46 |
| Diamond and Carbon-based Materials Research | Lifetime | 907 | US 206 | 96.91 |
| Neuropeptides and Animal Physiology | Lifetime | 925 | US 402 | 97.23 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 732 | US 322 | 97.32 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 809 | US 322 | 96.81 |
| Material Dynamics and Properties | Lifetime | 527 | US 200 | 96.94 |
| Nanopore and Nanochannel Transport Studies | Lifetime | 409 | US 149 | 95.42 |
| Uterine Myomas and Treatments | Lifetime | 759 | US 246 | 95.72 |
| Cancer Risks and Factors | Lifetime | 745 | US 388 | 95.21 |
| Urologic and reproductive health conditions | Lifetime | 825 | US 402 | 95.26 |
| Pregnancy-related medical research | Lifetime | 762 | US 276 | 92.34 |
| Bamboo properties and applications | Lifetime | 310 | US 23 | 90.47 |
| Axon Guidance and Neuronal Signaling | Lifetime | 861 | US 368 | 89.98 |
| Hippo pathway signaling and YAP/TAZ | Lifetime | 832 | US 345 | 88.13 |
| Chemotherapy-related skin toxicity | Lifetime | 573 | US 269 | 85.79 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 144 | US 42 | 97.57 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 401 | US 119 | 95.75 |
| Prostate Cancer Treatment and Research | 2021-2025 | 547 | US 201 | 95.28 |
| Urologic and reproductive health conditions | 2021-2025 | 182 | US 41 | 90.47 |
| Intraperitoneal and Appendiceal Malignancies | 2021-2025 | 190 | US 42 | 90.26 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 671 | US 196 | 92.55 |
| PARP inhibition in cancer therapy | 2021-2025 | 535 | US 196 | 86.01 |
| Endometrial and Cervical Cancer Treatments | 2021-2025 | 850 | US 183 | 88.64 |
| Urinary and Genital Oncology Studies | 2021-2025 | 645 | US 200 | 85.82 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 573 | US 138 | 66.46 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 780 | US 157 | 59.15 |
| Axon Guidance and Neuronal Signaling | 2021-2025 | 477 | US 155 | 45.12 |
| Mentoring and Academic Development | 2021-2025 | 412 | US 324 | 42.38 |